INT15742

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1987
Last Reported 2011
Negated 2
Speculated 1
Reported most in Body
Documents 37
Total Number 38
Disease Relevance 17.44
Pain Relevance 1.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (EPO) extracellular space (EPO) aging (EPO)
extracellular region (EPO)
Anatomy Link Frequency
arm 2
plasma 1
spinal cord 1
bone marrow 1
red blood cell 1
EPO (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 20 98.66 Very High Very High Very High
Spinal cord 2 98.44 Very High Very High Very High
cytokine 19 97.04 Very High Very High Very High
Pain score 2 95.28 Very High Very High Very High
Angina 18 91.44 High High
cva 33 90.48 High High
aspirin 3 90.32 High High
tolerance 11 89.52 High High
headache 15 82.32 Quite High
adenocard 4 81.28 Quite High
Disease Link Frequency Relevance Heat
Anaemia 496 100.00 Very High Very High Very High
Chronic Renal Failure 49 100.00 Very High Very High Very High
Malignant Neoplastic Disease 16 100.00 Very High Very High Very High
Renal Failure 29 99.84 Very High Very High Very High
Cancer 227 99.56 Very High Very High Very High
Spinal Cord Compression 2 98.44 Very High Very High Very High
Heart Failure 43 98.20 Very High Very High Very High
Hepatitis 21 97.88 Very High Very High Very High
Injury 41 97.64 Very High Very High Very High
Hypoxia 299 97.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A markedly anaemic, haemodialysis patient with a mixed deficiency of erythropoietin (EPO) and iron developed a life-threatening worsening of anaemia during an episode of severe rectal bleeding.
Negative_regulation (deficiency) of erythropoietin associated with anaemia and hemorrhage
1) Confidence 0.59 Published 1989 Journal Dan Med Bull Section Abstract Doc Link 2612227 Disease Relevance 0.28 Pain Relevance 0.09
A markedly anaemic, haemodialysis patient with a mixed deficiency of erythropoietin (EPO) and iron developed a life-threatening worsening of anaemia during an episode of severe rectal bleeding.
Negative_regulation (deficiency) of EPO associated with anaemia and hemorrhage
2) Confidence 0.59 Published 1989 Journal Dan Med Bull Section Abstract Doc Link 2612227 Disease Relevance 0.28 Pain Relevance 0.09
Chronic renal failure is characterized by anemia, which is principally caused by erythropoietin deficiency.
Negative_regulation (deficiency) of erythropoietin associated with anaemia and chronic renal failure
3) Confidence 0.59 Published 1989 Journal DICP Section Abstract Doc Link 2669369 Disease Relevance 0.89 Pain Relevance 0.15
In the control group the plasma EPO level was significantly higher (54.2 +/- 8 mU/ml) than in cancer patients before cycle I (17.1 +/- 2.5 mU/ml) and II (14.6 +/- 3.8 mU/ml) respectively.TNF administration was followed by a significant decline of plasma EPO both after the first (17.1 +/- 2.5 vs 9.0 +/- 1.5 mU/ml) and second cycle (14.6 +/- 3.8 vs 8.4 +/- 2.0 mU/ml) of TNF treatment.
Negative_regulation (decline) of EPO in plasma associated with cancer
4) Confidence 0.59 Published 2001 Journal J. Biol. Regul. Homeost. Agents Section Abstract Doc Link 11860225 Disease Relevance 1.25 Pain Relevance 0.12
However, mean Hb of the group "absolute iron deficiency" increased from baseline to month 6 and 12, in parallel to a decrease of EPO requirements, suggesting that physicians attempted to correct for iron deficit.
Negative_regulation (decrease) of EPO associated with anaemia
5) Confidence 0.59 Published 2008 Journal BMC Nephrol Section Body Doc Link PMC2621153 Disease Relevance 0.77 Pain Relevance 0
The erythropoietin level was found to be markedly decreased at 1 mU/ml.
Negative_regulation (decreased) of erythropoietin
6) Confidence 0.56 Published 2006 Journal Vasc Med Section Abstract Doc Link 16669411 Disease Relevance 0.19 Pain Relevance 0.14
Patients with renal failure are often anemic primarily because of diminished circulating erythropoietin and suppressed erythropoiesis in the bone marrow.
Negative_regulation (diminished) of erythropoietin in bone marrow associated with renal failure
7) Confidence 0.43 Published 1988 Journal Clin Pharm Section Abstract Doc Link 3280218 Disease Relevance 0.90 Pain Relevance 0.14
DOPPS II [8] also reported an EPO dose reduction of about 14% with subcutaneous administration, though a difference of only 3% was reported in the US.
Negative_regulation (reduction) of EPO
8) Confidence 0.43 Published 2008 Journal BMC Nephrol Section Body Doc Link PMC2621153 Disease Relevance 0.27 Pain Relevance 0
The rHuEPO costs are consequently reduced.


Negative_regulation (reduced) of rHuEPO
9) Confidence 0.43 Published 2002 Journal Blood Purif. Section Body Doc Link 12169845 Disease Relevance 0 Pain Relevance 0
Functional and pharmacokinetic outcomes after a single intravenous infusion of recombinant human erythropoietin in patients with malignant extradural spinal cord compression.
Negative_regulation (infusion) of erythropoietin in spinal cord associated with pain, malignant neoplastic disease and spinal cord
10) Confidence 0.43 Published 2007 Journal Clin Oncol (R Coll Radiol) Section Title Doc Link 17305256 Disease Relevance 0.20 Pain Relevance 0.24
At baseline, 71.1% of the patients received EPO beta subcutaneously.
Negative_regulation (received) of EPO beta
11) Confidence 0.43 Published 2008 Journal BMC Nephrol Section Body Doc Link PMC2621153 Disease Relevance 0.18 Pain Relevance 0
[Effectiveness of recombinant human erythropoietin in the treatment of transfusion-dependent anemia in patients on chronic dialysis].
Negative_regulation ([Effectiveness) of erythropoietin associated with anaemia
12) Confidence 0.43 Published 1987 Journal Wien. Klin. Wochenschr. Section Title Doc Link 3439185 Disease Relevance 0.23 Pain Relevance 0.06
Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis.
Negative_regulation (reduction) of erythropoietin
13) Confidence 0.43 Published 1991 Journal Aust N Z J Med Section Title Doc Link 1759917 Disease Relevance 0.27 Pain Relevance 0.07
Since our patients had a very low serum EPO level, we investigated the growth and differentiation of erythroid precursors in the absence of exogenously added EPO with normal and polycythemia vera (PV) cells used as controls.
Negative_regulation (had) of EPO associated with myelodysplastic syndromes
14) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916842 Disease Relevance 0.33 Pain Relevance 0
It is interesting that BaF3 cells, expressing a mutated EPOR unable to bind beta-Trcp, are hypersensitive to EPO, suggesting beta-Trcp-mediated ubiquitination represents a negative modulator of EPO-induced cellular proliferation [35].
Negative_regulation (hypersensitive) of EPO associated with hyperplasia
15) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2916842 Disease Relevance 0.18 Pain Relevance 0
Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

Anemia is a common complication of chronic kidney disease (CKD), with erythropoietin deficiency being the major contributing factor.

Negative_regulation (deficiency) of erythropoietin in kidney associated with chronic renal failure, anaemia and renal disease
16) Confidence 0.41 Published 2007 Journal International Journal of Nanomedicine Section Title Doc Link PMC2673829 Disease Relevance 0.68 Pain Relevance 0
A reduction in rHuEpo need was seen in the IV iron group.
Negative_regulation (reduction) of rHuEpo
17) Confidence 0.40 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 0.35 Pain Relevance 0
However, carbamylated Epo, a derivative of Epo, does not bind the homodimeric receptor yet has neuroprotective actions, facilitates clinical recovery in various animal models and appears to require the formation of a heteromeric receptor consisting of EpoR and CD131 [28,40].
Negative_regulation (derivative) of Epo
18) Confidence 0.39 Published 2009 Journal Malar J Section Body Doc Link PMC2785829 Disease Relevance 0.69 Pain Relevance 0.03
The clearest benefit of rhEPO in ESRD is a substantial reduction in transfusion dependency, which reduces the need for hospital admission and the risk of viral transmission.
Negative_regulation (reduction) of rhEPO associated with chronic renal failure
19) Confidence 0.39 Published 1999 Journal Clin. Nephrol. Section Abstract Doc Link 9988140 Disease Relevance 1.06 Pain Relevance 0.07
It was concluded that the two phosphate-buffered r-HuEPO concentrations formulated with and without the new stabilizer are pharmacokinetically equivalent.
Negative_regulation (equivalent) of r-HuEPO
20) Confidence 0.38 Published 2000 Journal Biopharm Drug Dispos Section Abstract Doc Link 11304719 Disease Relevance 0.10 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox